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Summary
 
Tumor necrosis factor 
 
a
 
 (TNF-
 
a
 
) is a proinflammatory cytokine. Its pleiotropic biological
properties are signaled through two distinct cell surface receptors: the TNF receptor type I
(TNFR-I) and the TNF receptor type II. Neither of the two receptors possesses tyrosine kinase
activity. A large majority of TNF-
 
a
 
–dependent activities can be mediated by TNFR-I. Re-
cently, c-Raf-1 kinase was identified as an intracellular target of a signal transduction cascade
 
initiated by binding of TNF-
 
a
 
 to TNFR-I. However, the mechanism engaged in TNF-
 
a
 
–dependent activation of c-Raf-1 kinase is still enigmatic.
Here we report that the cytosolic adapter protein Grb2 is a novel binding partner of TNFR-I.
Grb2 binds with its COOH-terminal SH3 domain to a PLAP motif within TNFR-I and with its
 
NH
 
2
 
-terminal SH3 domain to SOS (son of sevenless). A PLAP deletion mutant of TNFR-I fails
to bind Grb2. The TNFR-I/Grb2 interaction is essential for the TNF-
 
a
 
–dependent activation of
c-Raf-1 kinase; activation of c-Raf-1 kinase by TNF-
 
a
 
 can be blocked by coexpression of Grb2
mutants harboring inactivating point mutations in the NH
 
2
 
- or COOH-terminal SH3 domain,
cell-permeable peptides that disrupt the Grb2/TNFR-I interaction or transdominant negative
Ras. Functionality of the TNFR-I/Grb2/SOS/Ras interaction is a prerequisite but not suffi-
cient for TNF-
 
a
 
–dependent activation of c-Raf-1 kinase. Inhibition of the TNFR-I/FAN
 
(factor associated with neutral sphingomyelinase) interaction, which is essential for TNF-
 
a
 
–depen-
dent activation of the neutral sphingomyelinase, either by cell-permeable peptides or by dele-
tion of the FAN binding domain, prevents activation of c-Raf-1 kinase. In conclusion, binding
of the Grb2 adapter protein via its COOH-terminal SH3 domain to the nontyrosine kinase re-
ceptor TNFR-I results in activation of a signaling cascade known so far to be initiated, in the case
of the tyrosine kinase receptors, by binding of the SH2 domain of Grb2 to phosphotyrosine.
Key words: Grb2 • tumor necrosis factor • signal transduction • cell-permeable peptides • 
yeast two-hybrid system
 
T
 
NF-
 
a
 
 is a pleiotropic cytokine that triggers a variety of
biological effects on different target cell types (1). Two
different types of TNFR, which independently bind the
 
trimeric TNF-
 
a
 
 molecule, mediate these effects. According
to their apparent molecular masses, these receptors are des-
ignated as p55 (TNFR-I) or p75 (TNFR-II) (1–3). Neither
of the two receptors possesses tyrosine kinase activity. The
primary amino acid (aa)
 
1
 
 sequences of the cytoplasmic do-
mains of the two receptors display no significant homology,
suggesting that the two receptors interact with different
cellular proteins (4). Gene knockout experiments confirmed
that the two receptors control different signaling cascades
(5, 6). The majority of the biological effects of TNF-
 
a
 
 are
mediated by TNFR-I.
The two types of TNFR belong to the TNFR super-
family, which includes CD40 and the Fas antigen. Binding
of the ligand to these receptors results in receptor oligo-
merization and subsequent initiation of signal transduction
cascades. Apart from the death domain present in TNFR-I
and the Fas receptor, the cytoplasmic domain of TNFR-I
does not share significant homology to known cell surface
receptors, including the members of the TNFR superfam-
ily. Because a broad variety of cellular responses to TNF-
 
a
 
are mediated by TNFR-I and due to the lack of structural
similarities between TNFR-I and other cell surface recep-
tors, the understanding of the mechanism of signal trans-
duction through TNFR-I is of major biological interest.
TNF-
 
a
 
–dependent activation of phospholipase A2, pro-
tein kinase C, phosphatidylcholine-specific phospholipase C,
 
1
 
Abbreviations used in this paper: 
 
aa, amino acid; AP-1, activator protein 1;
CAP, ceramide-activated protein; CAT, chloramphenicol acetyltrans-
ferase; EGF, epidermal growth factor; n, neutral; NTA, nitrilotriacetic
acid; Smase, sphingomyelinase; SOS, son of sevenless. 
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and sphingomyelinases (Smases) is ascribed to TNFR-I (7–9).
Near to the COOH terminus, the so-called death domain of
 
z
 
80 amino acids was identified. In response to ligand bind-
ing, this domain recruits TNFR-associated death domain
(TRADD). TRADD interacts with FLICE/MACH1, a
death-promoting IL-1
 
b
 
–converting enzyme-like protease,
which is relevant for initiation of the apoptotic pathway
(10, 11). This domain is also involved in TNF-
 
a
 
–dependent
activation of acid Smase; the TNF-
 
a
 
–dependent activation
of the neutral (n)Smase is mediated by FAN, which binds
to the membrane proximal part (8, 12, 13).
Recently, c-Raf-1 kinase was identified as an intracellular
target of a signal transduction cascade initiated by binding of
TNF-
 
a
 
 to TNFR-I (14, 15). However, the mechanism en-
gaged in TNF-
 
a
 
–dependent activation of c-Raf-1 kinase
still remained enigmatic. In this study, a novel binding part-
ner of TNFR-I was identified, and its relevance for the
TNF-
 
a
 
–dependent activation of c-Raf-1 kinase was shown.
 
Materials and Methods
 
Yeast Two-Hybrid Cloning.
 
For construction of the lexA DNA
binding domain fusion, the vector plex202 (provided by R.
Brent, Harvard Medical School, Boston, MA) was used. The
coding sequences for the cytoplasmic domain of TNFR-I (aa
205–426) or for the truncated form (aa 206–345) were cloned in
frame into plex202. A Jurkat cDNA library fused to a synthetic
activation domain (16) was screened. The yeast strain EG48/
JK103 (17) was instrumental.
For analysis of the interaction of the cytoplasmic tail of
(cyt)TNFR-I with full-length Grb2 and the SH3 or SH2 domain–
mutated forms of Grb2, the matchmarker two-hybrid system was
instrumental (Clontech). The coding sequence for the cytoplasmic
domain of TNFR-I (aa 205–426) or the PLAP deletion mutant
was fused to the DNA binding domain of Gal4 by subcloning
pGBT9. The coding sequences for Grb2 (18), 
 
D
 
NSH3Grb2,
 
D
 
SH2Grb2, or 
 
D
 
CSH3Grb2 was fused to the activation domain
of Gal4 by subcloning into pGAD424. Here, the yeast strain
HF7c was used.
 
Immunoprecipitation.
 
Lysis of the cells was performed on ice in
20 mM Tris-HCl, pH 7.4, 137 mM NaCl, 0.05% Triton X-100,
1 mM PMSF, 0.2 U/ml aprotinin, 100 
 
m
 
g/ml leupeptin, and 1 mM
orthovanadate. The lysate was clarified by centrifugation, and the
supernatant was preabsorbed by 30-min incubation with protein
A/G–agarose (Santa Cruz Biotechnology). Purified supernatants
were incubated with antisera specific for c-TNFR-I (Santa Cruz
Biotechnology), for full length TNFR-I, Grb2, or son of seven-
less (SOS)1 (poly- and monoclonal sera from Santa Cruz Bio-
technology and signal transduction laboratories), respectively.
The complexes were precipitated by addition of protein A/G–
agarose. The precipitates were washed twice with 0.5 M LiCl and
0.1 M Tris, pH 7.4, and once with 0.01 M Tris, pH 7.4.
 
Western Blot Analysis.
 
For Western blot analysis, proteins were
separated by SDS-PAGE (19) and transferred onto cellulose ni-
trate membranes (0.45 
 
m
 
m; Schleicher & Schuell). Membranes
were washed for 30 min with PBST and preblocked for 15 min
in PBST containing 10% nonfat dry milk powder (blocking solu-
tion). Incubation with the first antibody diluted in blocking solu-
tion was performed for 2 h at room temperature. After extensive
washing with PBST, the bound antibody was detected by perox-
idase-conjugated secondary antibodies (Amersham Corp.). After
 
45 min of washing, the blots were developed using the ECL
Western blotting detection system (Amersham Corp.).
 
Construction of Expression Plasmids.
 
The sequence coding for full
length human TNFR-I was amplified from pHup60 (provided
by P. Goodwin, Immunex Corp.) by PCR using a forward
primer, which introduced the coding sequence for an NH
 
2
 
-
terminal histidine tag and subcloned into pCDNA.3. The se-
quence coding for the cytoplasmic domain of TNFR-I (aa 205–
426) was subcloned into the bacterial expression plasmid pQe8
(QIAGEN Inc.). For construction of the PLAP deletion mutant,
fragment I, nucleotide 256–1040, and fragment II, nucleotide
1050–1618, were amplified by PCR. In the case of fragment I,
the backward primer introduced a HindIII site; in the case of
fragment II, the forward primer harbored a HindIII site. The
HindIII-restricted fragments were ligated and subcloned into the
pCDNA.3 expression plasmid, generating pTNFR-I
 
D
 
PLAP.
The coding sequences for Grb2 and the dominant negative mu-
tants of the SH3 and SH2 domains (provided by J. Duyster, Uni-
versity of Ulm) were subcloned into pCDNA.3.
 
Transfection Experiments.
 
0.8 
 
3
 
 10
 
6
 
 70Z/3 and 293 cells were
transfected by lipofection using DOTAP (Boehringer Mannheim)
or the calcium phosphate procedure. For transfections, 5 
 
m
 
g of the
expression constructs was used, with the exception of 3xAP-1(acti-
vator protein 1)-chloramphenicol acetyltransferase (CAT), where
an amount of 1 
 
m
 
g was sufficient. Transfection efficiency was de-
termined by transfection of the cells with green fluorescent protein.
The transfection efficiency was 70–80%. Transfection efficiency
was normalized for by transfection with a plasmid coding for the
luciferase gene (pLuc). The CAT-ELISA was performed according
to the instructions of the manufacturer (Boehringer Mannheim).
 
Protein Purification.
 
Protein purification of the hexa-His–tag
fusion proteins was performed as described previously (20).
 
Kinase Assays.
 
15 min after stimulation with TNF-
 
a
 
 (100
U/ml; in the case of 70Z cells, 200 U/ml) or EGF (5 ng/ml), cells
were lysed in 20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 0.2 mM
EDTA, 1 mM EGTA, 10 mM sodium-
 
b
 
-glycerol-phosphate, 50
mM sodium fluoride, 0.5% Triton X-100, 1 mM sodium-ortho-
vanadate, 0.25 M sucrose, 0.5 mM PMSF (Sigma Chemical Co.),
0.15 U/ml aprotinin, and 2 
 
m
 
g/ml leupeptin. Insoluble material
was removed by centrifugation at 20,000 
 
g
 
 at 4
 
8
 
C for 15 min.
The protein concentration of the supernatant was determined by
a Bradford assay. 500 
 
m
 
g total protein was incubated for 15 min
at 4
 
8
 
C with protein A/G–agarose. The agarose beads were re-
moved by centrifugation, and the supernatant was incubated for 2 h
with c-Raf-1–specific antiserum. To precipitate the antigen–anti-
body complex, protein A/G–agarose was added again and incu-
bated for 1 h at 4
 
8
 
C. The complexes were sedimented by centrif-
ugation, and the pellet was washed twice in a buffer containing
100 mM Tris/HCl, pH 7.4, and 500 mM LiCl followed by a
wash in 10 mM Tris/HCl, pH 7.4. The pellet was resuspended in
kinase buffer as described previously (21).
 
Results
 
Grb2 Interacts with the Cytoplasmic Domain of TNFR-I.
 
To elucidate the mechanism of TNF-
 
a
 
–dependent activa-
tion of c-Raf-1 kinase, a yeast two-hybrid screen using the
lexA system was performed to identify adapter molecules
interacting with the membrane proximal region of TNFR-I.
Using a human Jurkat T cell cDNA library (16), a clone
encoding the COOH-terminal part of the adapter protein
Grb2 (aa 113–217) was identified. The coding sequence 
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consists of a truncated middle SH2 domain and a complete
COOH-terminal SH3 domain (Table I, top). The complete
adapter protein Grb2 consists of a middle SH2 domain
known to bind to phosphotyrosine residues and an NH
 
2
 
-
and COOH-terminal SH3 domain. The TNFR-I/Grb2 in-
teraction was confirmed using the Gal4 system by cotrans-
fection of the yeast strain HF7c with pGAD424Grb2 and
pGBT9cytTNFR-I (Table I, bottom). Only double-trans-
fected cells grew under the selection conditions.
To further confirm the interaction of Grb2 with the cy-
toplasmic domain of TNFR-I in another experimental sys-
tem, coprecipitation experiments using highly purified,
bacteria-derived Grb2 and cytTNFR-I were carried out.
These experiments demonstrated that (i) Grb2 is indeed a
binding partner of TNFR-I and (ii) no additional factors
are necessary for the binding of Grb2 to TNFR-I (Fig. 1 A).
The in vivo interaction of endogenous Grb2 with endog-
enous TNFR-I was studied by immunoprecipitation of cellu-
 
Table I.
 
Identification of the COOH-terminal SH3 Domain of Grb2 As a Binding Partner of the Cytoplasmic Domain of TNFR-I Using the 
Yeast Two-Hybrid System
 
DNA binding
domain hybrid
Activation
domain hybrid
Growth on
Leu
 
2
 
 medium Colony color
cTNF-RI aa 206–345
 
22
 
white
cTNF-RI aa 206–345
 
D
 
Grb2 aa113–217
 
1
 
blue
cTNF-RI aa 206–426
 
D
 
Grb2 aa113–217
 
1
 
blue
SYK
 
D
 
Grb2 aa113–217
 
2
 
white
 
2D
 
Grb2 aa113–217
 
2
 
white
DNA binding
domain hybrid
Activation
domain hybrid
Growth on
Leu
 
2
 
/His
 
2
 
/Trp
 
2
 
medium Colony color
cTNF-RI aa 206–426 Grb2
 
1
 
blue
cTNF-RI aa 206–426
 
D
 
NSH3Grb2
 
1
 
blue
cTNF-RI aa 206–426
 
D
 
CSH3Grb2
 
2
 
white
cTNF-RI aa 206–426
 
D
 
SH2Grb2
 
1
 
blue
Yeast strains harboring constructs encoding fusion proteins of the DNA binding domain of lexA and various fragments encoding the cytoplasmic do-
main of TNFR-I (aa 206–345 and aa 206–426) were transfected with constructs coding for fusion proteins of the Grb2 COOH-terminal SH3 do-
main and the lexA-activating domain.
Yeast strains transfected with pGBT9cTNFR-I (aa 205–426) were transformed with the vector containing the activation domain of Gal4 fused to
the coding sequences for (top) truncated Grb2 (aa 113–217), (bottom) full length Grb2, or (bottom) the inactivating point mutations in the SH3/
SH2 domains or SH2 domain. The experiments summarized at top were performed using the lexA system, and the experiments described at bottom
were performed using the Gal4 system.
Figure 1. Grb2 and TNFR-I
are direct binding partners. (A) Pu-
rified hexa-His–tagged cytoplasmic
domain of TNFR-I (cTNFR-I; aa
205–426) (lanes 1–3 and 5, 1 mg;
lane 4, 0.1 mg) was added to puri-
fied Grb2 (lanes 1–4, 6, and 7, 0.8
mg) in a volume of 300 ml. The
mixtures were precipitated by ad-
dition of Ni-NTA–agarose (lanes
2, 4, 6, and 7) (specific for hexa-
His–tagged c-TNFR-I), by a
polyclonal sera specific for Grb2.
Analysis of the precipitates for the
presence of Grb2 was performed
by Western blot using a monoclonal Grb2-specific antiserum. In lane 7, one-fifth of the precipitate was loaded to avoid overloading. Lanes 5 and 6 served
as negative controls. (B) Coimmunoprecipitation of Grb2 and TNFR-I from the lysate of 106 CCL13 cells. The lysates were precipitated by polyclonal
rabbit-derived sera against Grb2 or goat-derived serum against TNFR-I and analyzed for the presence of Grb2 (left) or TNFR-I (right) by Western blot,
using a mouse mAb specific for Grb2 or a polyclonal rabbit-derived serum specific for TNFR-I. Precipitations with an unrelated rabbit serum (rabbit
anti-PreS2; left, lane 4; right, lane 2) or an unrelated goat serum (goat anti-PreS2; left, lane 5; right, lane 4) served as negative control. Total cellular ly-
sates (left and right, lane 1) were used as positive controls. 
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lar lysates derived from CCL13 cells. Grb2 was coprecipitated
by a TNFR-I–specific antibody and, vice versa, TNFR-I was
coprecipitated by a Grb2-specific antiserum (Fig. 1 B). These
results demonstrate that Grb2 binds to TNFR-I in vivo.
Moreover, binding of Grb2 to TNFR-I seems to be constitu-
tive, as the presence of TNF-
 
a
 
 did not influence the amount
of coprecipitated TNFR-I by a Grb2-specific antiserum.
 
The COOH-terminal SH3 Domain of Grb2 Binds to a
PLAP Motif within TNFR-I.
 
In the next set of experi-
ments, the structural basis of the observed Grb2/TNFR-I
interaction was analyzed. SH3 domains are known to bind
to PXXP motifs (22–24). The membrane-proximal do-
main of TNFR-I harbors a PLAP motif within aa 237–240
as a potential binding site for the COOH-terminal SH3
domain of Grb2. Indeed, increasing concentrations of pep-
tides covering this sequence (functional peptide TTK-
PLAP) were able to compete the interaction of Grb2 with
the cytoplasmic domain of TNFR-I, as demonstrated by
coprecipitation experiments in vitro (Fig. 2 A).
The significance of this PLAP motif for the Grb2/
TNFR-I interaction was confirmed using the yeast two-
hybrid system. A deletion mutant of cytTNFR-I lacking the
PLAP motif (pGBT9cytTNFR-I
 
D
 
PLAP) failed to interact
with full length wild-type Grb2 (pGAD424Grb2) (Table I,
bottom). Furthermore, in vivo Grb2 could not be copre-
cipitated by Ni-NTA (nitrilotriacetic acid)–agarose from the
lysate of transfected 293 cells overproducing hexa-His–
tagged TNFR-I lacking the PLAP motif (Fig. 2 B). Ni-
NTA–agarose specifically precipitated the hexa-His–tagged
mutated receptor but not the wild-type receptor.
Essential structural requirements of the Grb2 adapter pro-
tein for interaction with TNFR-I were analyzed using the
yeast two-hybrid system. Functional inactivating mutations
of the NH
 
2
 
-terminal SH3 domain (pGADGrb2
 
D
 
NSH3) or
of the middle SH2 domain (pGADGrb2
 
D
 
SH2) did not af-
 
fect the interaction of Grb2 with cytTNFR-I. The inacti-
vating mutation of the COOH-terminal SH3 domain
(pGADGrb2
 
D
 
CSH3), however, abolished the interaction
with cytTNFR-I under these conditions (Table I, bottom).
These results confirm the dependence of the Grb2/TNFR-I
interaction on the COOH-terminal SH3 domain of Grb2.
 
Binding of Grb2 to the PLAP Motif within TNFR-I Is
Essential for the Activation of c-Raf-1 Kinase by TNF-
 
a
 
.
 
The
significance of TNFR-I/Grb2 interaction for TNF-
 
a
 
–depen-
dent activation of c-Raf-1 kinase was investigated by dif-
ferent experimental approaches. Cell-permeable peptides
were applied to disrupt the TNFR-I/Grb2 complex. These
peptides consist of two domains, a signal sequence derived
from the third helix of the antennapedia homeodomain,
which mediates membrane translocation (25), and the func-
tional domain covering the PLAP sequence of TNFR-I.
Presence of these peptides abolished TNF-
 
a
 
–dependent
activation of c-Raf-1 kinase (Fig. 3 A). This effect is spe-
cific, as the EGF-dependent activation of c-Raf-1 kinase
was not affected by the presence of these peptides. More-
over, a mutated peptide (KLAP) did not affect the TNF-
 
a
 
–dependent activation of c-Raf-1 kinase.
In addition, transfection of 70Z/3 cells, which lack func-
tional TNFR-I, with an expression plasmid encoding wild-
type TNFR-I restores the capability of TNF-
 
a
 
–dependent
activation of c-Raf-1 kinase. However, 70Z/3 cells trans-
fected with an expression plasmid encoding the PLAP de-
letion mutant of TNFR-I failed to respond to TNF-
 
a
 
stimulation with an activation of c-Raf-1 kinase (Fig. 3 B).
Finally, transfection of 293 cells with expression plas-
mids encoding inactivating point mutations in the NH
 
2
 
-
or COOH-terminal SH3 domain of Grb2 in both cases caused
a loss of TNF-
 
a
 
–dependent induction of c-Raf-1 activity. The
mutation of the middle SH2 domain, however, did not affect
the TNF-
 
a
 
–dependent activation of c-Raf-1 kinase (Fig. 3 C).
Figure 2. A PLAP motif in the cytoplasmic domain of TNFR-I mediates the interaction with Grb2. (A) Purified hexa-His–tagged cytTNFR-I (1 mg)
was added to cellular lysate (500 mg) derived from TNF-a–stimulated 293 cells. Coprecipitation of Grb2 by addition of Ni-NTA–agarose, which precip-
itates the 6H-cytTNFR-I, was inhibited by increasing concentrations of a peptide (functional peptide [FP], lanes 4–6) harboring the recognition se-
quence TTKPLAP, whereas a mutated peptide (MP) (TTKKLAP, lanes 7–9) did not significantly affect the interaction of Grb2 and TNFR-I. An unre-
lated peptide served as additional control (CP) (DRQIKIWFQNRRMKWKK; lanes 1–3). The peptides were used in concentrations of 0.1 (lanes 2, 5,
and 8) and 4 mg/ml (lanes 3, 6, and 9). The precipitates were analyzed by Western blot using a Grb2-specific antiserum. (B) Left: after transient transfec-
tion of 293 cells with p6H-TNFR-I (encoding for a fusion protein of an NH2-terminal hexa-His tag and full length TNFR-I) (lanes 5 and 6), with p6H-
TNFR-ID-PLAP (encoding for the hexa-His–tagged PLAP deletion mutant (lanes 1–3), or with the vector pCDNA.3 (lane 4), cellular lysates were pre-
cipitated by addition of Ni-NTA–agarose (lanes 2, 4, and 5) by a Grb2-specific polyclonal serum (lanes 3 and 6) or by an unrelated rabbit-derived serum
(anti-PreS2; lane 1). The subsequent Western blot analysis was performed using a Grb2-specific, mouse-derived mAb. Right: lysates derived from p6H-
TNFR-I– (lanes 1, 2, 4, and 5), p6H-TNFR-IDPLAP– (lanes 3 and 6), or pCDNA.3- (lane 7) transfected cells were precipitated with Ni-NTA–agarose
(lanes 4–6), a Grb2-specific polyclonal rabbit derived serum (lanes 2, 3, and 7), or an unrelated rabbit serum (anti-PreS2; lane 1). The precipitates were
analyzed using a hexa-His tag–specific antibody. 
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SOS Is Part of the Grb2/TNFR-I Complex.
 
In the case
of tyrosine kinase receptor–dependent activation of c-Raf-1
kinase, the SH3 domains of Grb2 are known to interact with
the SOS proteins, which interfere with Ras (22, 26, 27).
Based on the observation that integrity of the NH2-terminal
SH3 domain of Grb2 is essential to trigger TNF-a–depen-
dent activation of c-Raf-1 kinase, it was investigated whether
Grb2, while bound to TNFR-I with its COOH-terminal
SH3 domain, still interacts with SOS1/2 proteins with its
NH2-terminal SH3 domain. Hexa-His–tagged cytoplasmic
domain of TNFR-I was added to cellular lysates derived
from 293 cells. The mixture was precipitated using either anti-
Grb2– or anti-SOS1/2–specific antibodies, or Ni-NTA–aga-
rose, which specifically precipitates 6H-cytTNFR-I. Western
blot analysis of the precipitates demonstrated that cytTNFR-I
indeed coprecipitates with both Grb2 and SOS (Fig. 4 A).
Transfection of 293 cells with an expression plasmid
coding for a transdominant negative Ras mutant (RasN17)
caused a loss of TNF-a–dependent activation of c-Raf-1
kinase. These results demonstrated that the TNF-a–depen-
dent activation of c-Raf-1 kinase requires the integrity of
the TNFR-I-Grb2-SOS-Ras pathway.
The TNFR-I/Grb2 Interaction Is Essential for the TNF-depen-
dent Activation of AP-1. The physiological significance of
Grb2-mediated activation of c-Raf-1 kinase upon stimula-
tion with TNF-a was investigated by reporter gene assays.
Cotransfection of an AP-1–driven reporter gene plasmid
(p3xAP-1–CAT) (28) with the expression plasmids encod-
ing the three Grb2 mutants harboring the inactivating
point mutations in the NH2- or COOH-terminal SH3 do-
main or those in the middle SH2 domain, with a transdom-
inant negative Ras mutant (pRasN17), or with a transdom-
inant negative mutant of c-Raf-1 kinase (pHCR13.1) (29)
caused, with exception of pDSH2Grb2, a loss of TNF-
a–dependent induction of the reporter gene (Fig. 3 D). This
shows (i) that the integrity of the TNFR-I/Grb2 interaction
is a prerequisite for the TNF-a–dependent activation of
AP-1, (ii) that, in addition to the COOH-terminal SH3 do-
main, the NH2-terminal SH3 domain of Grb2 is essential for
the activation of AP-1 by TNFR-I, and (iii) that Ras is in-
volved in TNF-a–dependent signal transduction.
Activation of c-Raf-1 Kinase Requires TNFR-I/FAN Inter-
action. The PLAP-dependent Grb2/TNFR-I interaction
is essential but not sufficient for TNF-a–dependent acti-
Figure 3. The TNFR-I/Grb2 interaction is
essential for TNF-dependent activation of
c-Raf-1 kinase and subsequent activation of
AP-1. (A) 12-h serum-deprived 293 cells were
grown for 6 h in the presence of cell-perme-
able peptides (15 mg/ml) covering the PLAP
sequence (functional peptide [FP]: DRQIKI-
WFQNRRMKWKKTTKPLAP; left, lane 4;
right, lane 5) or a mutated peptide ([MP]:
DRQIKIWFQNRRMKWKKTTKKLAP;
left, lane 2; right, lane 4). Thereafter, cells were
exposed for 15 min to TNF-a (100 U/ml)
(left, lanes 1, 2, and 4) or to EGF (5 ng/ml)
(right, lanes 3–5) in addition to the cell-perme-
able peptides. Activity of c-Raf-1 kinase was
determined by immunocomplex assay using
6H-MEK as substrate and compared with un-
stimulated cells (left, lane 3; right, lanes 1 and
2). (B) 70Z3 cells were transfected with
pCDNA.3 (lane 1), p6H-TNFR-I (lane 2),
and p6H-TNFR-IDPLAP (lane 3). After stim-
ulation with TNF-a (200 U/ml), the activity
of c-Raf-1 kinase was determined by immuno-
complex assay. Activity of c-Raf-1 kinase in
pCDNA.3-transfected cells was set arbitrarily
as 1. (C) Immunocomplex assay of c-Raf-1
kinase activity in 293 cells transiently trans-
fected with pCDNA.3 (lanes 1, 2, and 6),
pDNSH3-Grb2 (lane 3), pDSH2Grb2 (lane 4),
and pDCSH3Grb2 (lane 5) after TNF-a (lanes
3–6) or EGF (lane 2) stimulation. Unstimulated
cells (lane 1) served as negative control. (D)
Reporter gene assay in 293 cells transiently
cotransfected with pCDNA.3, pDNSH3-Grb2,
pDSH2Grb2, pDCSH3Grb2, and pHCR13.1
encoding a transdominant negative mutant of
c-Raf-1 kinase 20 or pRasN17 and the re-
porter plasmid p3xAP-1–CAT after TNF-a
stimulation (100 U/ml) for 24 h. The determi-
nation of the induced CAT amount was per-
formed using a commercially available ELISA
system. Activities given as fold induction are
mean values of two independent experiments.1712 Grb2 Binds to TNFR-I
vation of c-Raf-1 kinase (15). Transfected 70Z/3 cells pro-
ducing a deletion mutant of TNFR-I (TNFR-ID308–340),
which lacks the ability to activate nSMase, fail to respond
with activation of c-Raf-1 kinase upon stimulation of
TNFR-I (8, 12). This mutant lacks the FAN binding do-
main (13, 30). FAN was recently discovered to mediate the
TNF-a–dependent activation of nSMase (12, 13) (Fig. 4 B).
In addition, disruption of the TNFR-I/FAN interaction by
cell-permeable peptides (25) covering the binding domain
blocked the TNF-a–dependent activation of c-Raf-1 kinase
(Fig. 4 C). These data confirm the relevance of TNF-
a–dependent activation of nSMase for induction of c-Raf-1
kinase activity.
Discussion
Based on our results, we propose that the TNF-a–depen-
dent activation of c-Raf-1 kinase is mediated through at
least two cooperative domains that are both indispensable.
The cytoplasmic tail of TNFR-I interacts via a PLAP motif
with the COOH-terminal SH3 domain of the adapter pro-
tein Grb2. The NH2-terminal SH3 domain of Grb2 inter-
feres with SOS, therefore linking TNFR-I to c-Raf-1 ki-
nase involving Ras (26). In contrast to the situation, in the
case of tyrosine kinase receptors, in which Grb2 interacts
with its middle SH2 domain with phosphotyrosine, this
Grb2/SOS/Ras-dependent pathway is not sufficient for ac-
tivation of c-Raf-1 kinase. A second domain is required.
This domain was recently shown to bind FAN (12, 13). The
TNFR-I/FAN interaction is essential for TNF-a–depen-
dent activation of nSMase (8, 12, 13, 31, 32). The hydro-
lysis of sphingomyelin catalyzed by nSMase generates cer-
amide, which can finally activate ceramide-activated protein
(CAP) kinase. CAP kinase recently has been shown to bind
to TNF-a–dependent activated c-Raf-1 kinase (15). Both
pathways, the Grb2-SOS-RAS pathway and the activated
CAP kinase pathway, might cooperatively mediate TNF-
a–dependent activation of c-Raf-1 kinase (Fig. 4 D).
Figure 4. SOS coprecipitates with
Grb2 and TNFR-I. (A) In the pres-
ence (1; lanes 1–4) or absence (2;
lanes 5–7) of purified hexa-His–tagged
cyt(c)TNFR-I (1 mg), cellular lysates
derived from 293 cells were precipi-
tated with Ni-NTA–agarose (lanes 2
and 5), SOS1/2-specific antiserum
(lanes 3 and 6), and Grb2-specific anti-
serum (lanes 4 and 7). The precipitates
were analyzed for the presence of
cytTNFR-I by Western blot using a
hexa-His tag–specific antibody. In
lane 1, the mixture of cytTNFR-I com-
bined  with cellular lysate was loaded
directly as the positive control. (B)
70Z3 cells stably producing wild-type
TNFR-I or a deletion mutant
(TNFRID308–340) lacking the
nSMase-activating domain were stim-
ulated with TNF-a (200 U/ml) for 15
min, and c-Raf-1 kinase activity was
determined by immunocomplex as-
say. (C) 12-h serum-deprived 293 cells
were grown for 6 h in the presence of
cell-permeable peptides (lanes 2 and 4)
covering the FAN binding sequence
(functional peptide [FP], 5 mg/ml).
Thereafter, cells were exposed for 15
min to TNF-a (100 U/ml; lanes 2 and
3) or EGF (5 ng/ml; lanes 1 and 5) in
addition to the cell-permeable pep-
tides. Activity of c-Raf-1 kinase was
determined by immunocomplex assay
using 6H-MEK as substrate. (D) Sche-
matic representation of the proposed
model of TNF-a–dependent activa-
tion of c-Raf-1 kinase. A PLAP motif
recruits the Grb2 adapter protein
through its COOH-terminal SH3
domain to TNFR-I. The NH2-termi-
nal SH3 domain of Grb2 interacts
with SOS, which recruits via Ras
c-Raf-1 kinase to the membrane. TNF-a–dependent activation of nSMase is mediated by binding of FAN to a distinct domain of TNFR-I (12, 13).
Activation of nSMase results in the production of ceramide and, consequently, in an activation of CAP kinase. Both TNF-a–responsive pathways, the
activation of Ras via Grb2 and the activation of nSMase, cooperatively stimulate c-Raf-1 kinase.1713 Hildt and Oess
Although TNFR-I does not belong to the tyrosine ki-
nase receptor family, Grb2 has been identified as a binding
partner. In contrast to the interaction with phosphoty-
rosine, which is mediated through its middle SH2 domain,
Grb2 interacts here with TNFR-I via its COOH-terminal
SH3 domain. Although there is an obvious difference on
the molecular level of the receptor/adapter interaction, in
both cases, binding of Grb2 to the receptor is essential for
triggering activation of c-Raf-1 kinase. Whereas for tyro-
sine kinase receptors the Grb2-SOS-Ras pathway seems to
be sufficient for activation of c-Raf-1 kinase, in the case of
TNFR-I, a second pathway via CAP kinase is involved.
One possible explanation is that the interaction of SOS
with the NH2-terminal SH3 domain of Grb2 is not strong
enough to recruit c-Raf-1 kinase to the membrane and, in
addition, the membrane-associated CAP kinase is required.
Moreover, the binding of Grb2 to the PLAP motif in the
cytoplasmic domain of TNFR-I is constitutive. Therefore,
TNF-a–dependent activation of nSMase provides a trigger
for the TNF-a–dependent activation of c-Raf-1 kinase.
In conclusion, we demonstrate that the tyrosine kinase
adapter protein Grb2 is a novel binding partner of TNFR-I
and is essential for TNF-a–dependent activation of c-Raf-1
kinase.
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